ValiRx updates market on 'significant' 2015
19th May 2016 15:44
(ShareCast News) - Lifesciences company ValiRx reported on a "significant year" on Thursday, talking up its capital restructure and technical advancements in the 2015 calendar year. The AIM-traded firm, which focuses on cancer therapeutics and diagnostics for personalised medicine, said its Phase I/
Read moreValiRx achieves success in latest VAL201 trial
16th Feb 2016 13:17
(ShareCast News) - ValiRx was pressing ahead with the trial process for its VAL201 trial treatment on Tuesday, following positive results from the most recent tranche of test patients. The AIM-traded life science company, with a focus on cancer diagnostics and therapeutics for personalised medicine,
Read moreValiRx confident in two ongoing clinical trials
9th Feb 2016 14:17
(ShareCast News) - ValiRx was confident in the potential of two of its compounds on Tuesday, in its quarterly update on its ongoing clinical trials. The AIM-traded life science firm, with a focus on cancer diagnostics and therapeutics for personalised medicine, said that recent testing had shown VAL
Read moreValirx's lung cancer treatment receives positive results
2nd Sep 2014 09:27
Valirx, the developer and producer of technology used in oncology therapeutics, has received positive results from the studies on one of its lung cancer treatments. The studies on treatment VAL401 were carried out by Valiseek, Valirx's joint venture company with Tangent Reprofiling, and demonstrate
Read moreTuesday broker round-up UPDATE
10th Jun 2014 09:45
ASOS: Goldman Sachs reduces target price from 6250p to 5750p, while upgrading to strong buy. Avon Rubber: Investec lowers target price from 690p to 680p and downgrades from buy to add. BAE Systems: Investec downgrades from add to hold with a target price of 430p. BG Group: Exane downgrades to neu
Read moreValiRX reports encouraging progress despite losses
5th Sep 2013 11:44
ValiRx, a biopharmaceutial company with a focus on the treatment of cancer, said while losses had widened in the first half it had made "excellent" advances in its clinical and pre-clinical development pipeline. It reiterated that it expected results from the first stage of clinical trials for its
Read moreValiRx granted patent in Australia for VAL201 targeting cancer
25th Apr 2013 10:02
ValiRx has been granted a patent for its lead therapeutic compound VAL201 for the treatment of breast, prostate, breast and ovarian cancer in Australia. The cancer diagnostics company said VAL201 has shown efficacy in prostate, breast and ovarian cancer as well as addressing endometriosis or hormon
Read moreValiRx to present at key Cancer Conference
2nd Apr 2013 08:41
Shares in life science company ValiRx rose on Tuesday morning after the AIM-listed company announced that it would be presenting at the American Association for Cancer Research Conference this year. The conference, which was attended by approximately 17,000 delegates last year, is seen as a key eve
Read moreValiRx appoints COO to help build portfolio
21st Feb 2013 13:17
Biotech firm ValiRx has appointed a Chief Operating Officer to assist in building and adding value to its portfolio of technologies and to coordinate ValiRx's commercial strategy. Samual Ogunsalu has a background in Microbiology and Biochemical engineering and has 15 years' experience in the identi
Read moreSmall cap round-up: InterQuest, ValiRx, Aeorema Comms
22nd Nov 2012 15:56
InterQuest has warned that trading during the summer, traditionally its strongest period, has been sluggish. As a result underlying earnings before interest, tax, depreciation and amortisation (EBITDA) will be in the region of 2.2m pounds. This does not include an exceptional credit of about 0.85m p
Read moreContract wins round-up: LO-Q, Motive TV, Plexus ...
11th Oct 2012 09:50
Lo-Q has announced its second contract win of the week, as an unnamed major US theme park operator has signed up to use the firm's virtual queueing system at two sites in the US. Revenue associated with the agreement is expected to scale gradually, over time. In addition, the deal grants that Lo-Q's
Read moreSmall cap round-up: ValiRx, Transense, Sweett
29th May 2012 08:37
Shares in ValiRx, the life sciences firm, leapt almost 40% on Tuesday after it said independent trials had confirmed the effectiveness of its prostate cancer drug VAL201. The firm said the "significant and substantively important findings" showed its drug reduced the spread of secondary tumours by u
Read moreSmall caps round-up: Cello, DDD, Kewill...
15th May 2012 13:12
Marketing firm Cello Group has reported good trading during the first three months of the year, reflecting 'the strong pipeline of work secured at the end of 2011 and a solid flow of bookings'. The research and consulting division was a strong performer, while the group's focus on the pharmaceutic
Read moreSmall caps round-up: James Cropper, ValiRx, ReNeuron
27th Apr 2012 14:20
James Cropper, a specialist paper and materials group, has said that pre-execptional profit before tax is set to be in line with market expectations. The company also said its previously announced restructuring process will reduce the size of the UK workforce by eight per cent during the current yea
Read moreSmall caps round-up: Rock Solid, ValiRx, InternetQ, Quindell
2nd Apr 2012 13:36
Rock Solid Images, an oil equipment, services and distribution firm, has received an offer from Thalassa Holdings to acquire up to 25.89 per cent of the company for 0.48p per share in cash. Rock Solid is concerned that Thalassa has provided no evidence that they will bring any "added economic or ind
Read more